Pharmacy Practice Faculty/Staff Directory

Sherrill Brown

DVM, PharmD, BCPS, Director

Contact

Education

Drug Information Residency, University of Tennessee Health Science Center and Methodist Healthcare - University Hospital, Memphis, Tennessee (2004)

Doctor of Pharmacy, University of Missouri - Kansas City (2003)

Doctor of Veterinary Medicine, University of Missouri - Columbia (1992)

Courses Taught

PHAR 350 Introduction to Drug Information

PHAR 550 Drug Literature Evaluation

PHAR 583 Drug Information APPE

Research Interests

Drug Information and Literature Evaluation

 

Selected Publications

Brown SJ.  Pharmacy technicians and improving onychomycosis treatment outcomes.  J Pharm Technol 2018 Nov 28. doi: 10.1177/8755122518815057

Brown S.  Pharmacy law, regulations, and standards.  In: Bachenheimer BS, editor.  Manual for Pharmacy Technicians. 5th edition.  Bethesda (MD): American Society of Health-System Pharmacists.  Under review.

Miller SJ, Brown S.  Overweight and obesity.  In: Krinsky DL, editor.  Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care.  19th edition.  Washington, DC: American Pharmacists Association; 2018.  .

Madson KA, Brown S.  Rivastigmine: dementia with Lewy bodies.  Hosp Pharm 2016;51(2):129-131.

Brown S.  Putting your best foot forward in the management of onychomycosis (December 28, 2015).  Pharmacy Times Continuing Education. Available at: https://www.pharmacytimes.org/landing/768.

Brown SJ.  Onychomycosis for Pharmacists: Part 1, Overcoming Common Misconceptions About Onychomycosis (June 30, 2015).  Power-Pak C.E.®  Available at: http://www.powerpak.com/course/preamble/111579.

Brown SJ.  Efficacy of fluconazole for the treatment of onychomycosis.  Ann Pharmacother 2009;43:1684-1691. 

Brown SJ.  The role of vitamin D in multiple sclerosis.  Ann Pharmacother 2006;40:1158-1161.

Brown S, Thormahlen G, Chilson C, et al. Drugs given by IV intermittent or continuous infusion in adults. Hospital Pharmacy Wall Chart.  June 2006.

Chilson CN, Brown SJ.  The role of botulinum toxin type A (BOTOX) in the prophylactic treatment of migraine headaches.  Ann Pharmacother 2005;39:2081-2085.